"Hepatitis C, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Descriptor ID |
D019698
|
| MeSH Number(s) |
C02.440.440.120 C02.782.350.350.120 C06.552.380.350.120 C06.552.380.705.440.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hepatitis C, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Hepatitis C, Chronic".
This graph shows the total number of publications written about "Hepatitis C, Chronic" by people in this website by year, and whether "Hepatitis C, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2001 | 5 | 0 | 5 |
| 2002 | 2 | 2 | 4 |
| 2003 | 5 | 0 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 7 | 0 | 7 |
| 2008 | 5 | 0 | 5 |
| 2009 | 7 | 4 | 11 |
| 2010 | 14 | 3 | 17 |
| 2011 | 18 | 0 | 18 |
| 2012 | 10 | 1 | 11 |
| 2013 | 15 | 0 | 15 |
| 2014 | 13 | 0 | 13 |
| 2015 | 15 | 0 | 15 |
| 2016 | 15 | 0 | 15 |
| 2017 | 18 | 1 | 19 |
| 2018 | 13 | 3 | 16 |
| 2019 | 18 | 2 | 20 |
| 2020 | 7 | 0 | 7 |
| 2021 | 10 | 0 | 10 |
| 2022 | 12 | 0 | 12 |
| 2023 | 12 | 0 | 12 |
| 2024 | 4 | 1 | 5 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepatitis C, Chronic" by people in Profiles.
-
Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study. Lancet Child Adolesc Health. 2025 04; 9(4):248-254.
-
Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
-
Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program. Gastroenterology. 2024 Dec; 167(7):1429-1445.
-
Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center. J Natl Compr Canc Netw. 2024 05 10; 22(2 D).
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology. 2025 Jan 01; 81(1):358-379.
-
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries. Hepatology. 2024 08 01; 80(2):440-450.
-
Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection. Liver Int. 2024 Jun; 44(6):1383-1395.
-
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline. Ann Intern Med. 2023 12; 176(12):1648-1655.
-
Outcomes of kidney, liver, and simultaneous liver and kidney transplants from hepatitis c infected donors to hepatitis c na?ve recipients: A large single center experience. Clin Transplant. 2024 01; 38(1):e15161.